Dihexa: the potency figure everyone quotes, and what it was measured against

Almost every description of this compound leads with a number in the millions. The number is real and it comes from a published experiment, but it describes a specific measurement in cell culture rather than anything observed in a person. Understanding what was measured is most of what there is to understand here.

Where the compound came from

Established clinical use Dihexa is a small synthetic molecule derived from angiotensin IV, developed in academic laboratories at Washington State University. Angiotensin IV had been observed to improve performance in rodent memory tasks, and the derivative was built to survive metabolism, cross into the brain and retain the activity. Its proposed mechanism is potentiation of hepatocyte growth factor signalling at its receptor, c-Met, which is involved in synapse formation.

Animal-only or theoretical The potency figure comes from a cell-culture assay of spine and synapse formation, in which the concentration producing an effect was compared with that of brain- derived neurotrophic factor in the same system. A ratio between two concentrations in a dish is a statement about relative potency in that assay. It is not a statement about effect size, about the brain, or about anyone’s memory, and it is quoted as though it were all three.

The animal work is more informative and still preclinical: improvement on water-maze performance in rodent models of cognitive impairment, including scopolamine-induced deficits and lesion models. That is a real body of published work. It is the same stage at which a great many compounds have looked convincing and then not translated.

The human gap, and the dose problem

Animal-only or theoretical No published controlled human trial exists. The app records a research range of 1–10mg by oral or intranasal route in short runs, which reflects community practice rather than a study, and the tenfold width of that range is itself informative: nobody knows what the right amount is because nobody has measured it in a person.

That width matters more than usual for this compound. A molecule described as extremely potent, dosed in milligrams by a route with variable absorption, gives no basis for judging whether an effect or an absence of one reflects the compound or the delivery. Intranasal and oral administration of the same substance are not interchangeable, and no bioavailability data settles which the range refers to.

Assessment is a further problem. The app records cognitive and mood self-assessment and no blood monitoring, which is accurate — there is no marker. Self-assessed cognition is the measurement most vulnerable to expectation in the whole of this field, and it is the only one available here. A structured, timed task repeated on the same schedule is weak evidence but is better than a recollection.

The risk that follows from the mechanism

Animal-only or theoretical The HGF/c-Met axis is not a neurological curiosity. It is a growth factor pathway that is amplified or activated in several cancers, and it is an active oncology drug target — approved medicines exist that inhibit c-Met precisely because that signalling drives tumour growth. A compound designed to potentiate the same axis raises an obvious question in the opposite direction, and no human data addresses it.

The app lists this among the drawbacks and it deserves the emphasis. There is no test that would detect the concern, no dose known to be below it, and no duration established as safe. This is the reason the page carries no recommendation and the reason anyone considering it, particularly with any personal or family cancer history, should be raising it with a doctor first.

Compared with the other compounds on this site discussed for cognition — semax and cerebrolysin both have decades of human use and published trials in their countries of origin, whatever the quality of those trials — dihexa is earlier by a wide margin. It is a preclinical academic compound, and material sold under the name comes with no verified identity. This site names no vendor.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Dihexa, verbatim. None of the analytes it names has a page here yet.

Drawbacks and risks the app records

From the app’s own entry. The tumour item and the dosing-accuracy item are connected: an extremely potent compound with no established range is hard to keep below a threshold nobody has located.

• Very limited human data — mostly animal studies
• Long-term safety completely unknown
• Difficult to dose accurately due to extreme potency
• Theoretical risk: synaptogenesis could promote certain tumor growth
• Not FDA approved
• Sourcing and purity verification critical

Questions people actually ask

Is dihexa really millions of times stronger than BDNF?

That ratio comes from a cell-culture assay comparing the concentrations at which each promoted synapse formation. It describes relative potency in that dish, not the size of any effect and not anything measured in a person.

Are there human trials?

No published controlled trial exists. The evidence is preclinical: cell culture and rodent cognition models.

Oral or intranasal?

The app records both within one range, and no bioavailability data distinguishes them. That is a reason for caution rather than a choice this page can resolve.

What is the cancer concern?

The compound potentiates HGF/c-Met signalling. That pathway drives growth in several cancers and is the target of approved inhibitors. Potentiating it has not been studied in humans, and it is a question for a doctor rather than a message board.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.